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Abstract
Background:  A dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been
proposed as an important pathogenic factor in depression. Genetic variants of FKBP5, a protein of
the HPA system modulating the glucocorticoid receptor, have been reported to be genetically
associated with improved response to medical treatment and an increase of depressive episodes.
Methods: We examined three single nucleotide polymorphisms (SNPs) in FKBP5, rs4713916 in the
proposed promoter region, rs1360780 in the second intron and rs3800373 in the 3'-untranslated
region (3'-UTR), in a case-control study of Caucasian origin (affective psychosis: n = 248; controls:
n = 188) for genetic association and association with disease related traits.
Results: Allele and genotype frequencies of rs4713916, rs1360780 and rs3800373 were not
significantly different between cases and controls. Two three-locus haplotypes, G-C-T and A-T-G,
accounted for 86.2% in controls. Odds ratios were not increased between cases and controls,
except the rare haplotype G-C-G (OR 6.81), representing 2.1% of cases and 0.3% of controls. The
frequency of rs4713916AG in patients deviated from expected Hardy-Weinberg equilibrium, the
genotype AA at rs4713916 in monopolar depression (P = 0.011), and the two-locus haplotype
rs1360780T – rs3800373T in the total sample (overall P = 0.045) were nominally associated with
longer continuance of disease.
Conclusion: Our data do not support a significant genetic contribution of FKBP5 polymorphisms
and haplotypes to affective psychosis, and the findings are inconclusive regarding their contribution
to disease-related traits.
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Background
Collaterally to a complex dysregulation of neurotransmis-
sion, hyperactivity of the hypothalamic-pituitary-adrenal
(HPA) axis has been proposed as an essential pathogenic
factor in depressive disorders [1]. As a predictor of clinical
improvement normalisation of the HPA-system is one of
the basic findings [2] as well as a partial cortisol resistance
among depressive patients resulting in an impaired nega-
tive feedback and elevated cortisol levels [1]. In search for
the genetic and functional mechanisms underlying the
HPA-dysfunction in depression, recent research focused
on genes involved in HPA-axis regulation, such as the
genes for corticotropin-releasing hormone or the gluco-
corticoid receptor (GR) with several cochaperones.
Among these FKBP5 gained growing interest.
FKBP5, synonymous to FKBP51 and FKBP54, is located on
chromosome 6p21, a chromosomal region associated
with bipolar disorder and psychosis [3] and consists of 10
exons spanning ~156 kb (UCSC Genome Browser, release
August 2004). FKBP5 is mainly expressed in brain, and in
a wide range of human cell tissue, including muscle, liver,
and thymus. Functionally, cortisol induces the FKBP5
expression by glucocorticoid-response-elements in
human lymphocytes [4]. The protein of 457 amino acids
is composed of three domains, two immuno-suppressants
binding sites and a tetratrico-peptide-repeat domain [5].
FKBP5 reduces the receptor affinity for cortisol by a com-
plex interaction with the mature hetero-oligomeric gluco-
corticoid receptor complex and is thought to diminish the
dynein binding and nuclear translocation of the glucocor-
ticoid-receptor complex [6]. In addition, FKBP5 has been
associated with glucocorticoid-resistance in new world
monkeys which results from both expression of GRs that
are less responsive and overexpression of FKBP5 that fur-
ther reduces GR responsiveness [7].
In a mutation scan aiming to detect genetic equivalents of
HPA-dysregulation among the cochaperon gene cluster in
depression, thirty single-nucleotide-polymorphisms
(SNPs) were detected at the FKBP5 locus, but no overall
genetic association with disease was traceable in a panel of
317 patients with depression [8]. Three SNPs, namely
rs4713916 in the putative promoter region, rs1360780 in
the second intron, and rs3800373 in the 3'-UTR region,
however, were found associated with improved response
to antidepressant treatment. Patients with the
rs1360780TT genotype had more than twice as many
depressive episodes in the past. In lymphocyte cell-culture
studies FKBP5 levels were increased for the risk TT-geno-
type, and the correlation of plasma cortisol and FKBP5
mRNA level was interpreted as a firm control of the HPA-
axis by FKBP5 [8]. Given these genetic and clinical find-
ings, we tried to replicate the association of the FKBP5
gene locus with depression and disease-related variables
in a case-control study of probands with similar ethnic
background.
Methods
The sample encompassed 248 cases (154 males) with
recurrent depression and bipolar disorder according to
ICD10 with a mean age of 48.1 years. [9]. Patients also ful-
filled the more restricted criteria of monopolar depression
(n = 57), and manic depression (n = 191; Table 1) in dif-
ferentiated psychopathology [10]. Leonhard's conception
of manic-depression displays some important differences
compared to current conceptions as of bipolar affective
psychoses. Manic-depression in differentiated psychopa-
thology represents a distinct clinical and nosological
entity. The essential criteria are bipolarity with a melan-
cholic or manic basic syndrome, or presence of mixed
states or partial states with lability of the affect in a unipo-
lar course with complete remission after each episode. By
contrast monopolar affective psychoses are characterized
by distinct affective syndromes recurring in each episode
in the same form. In our sample cases with manic-depres-
sion encompassed 77% of the total sample of affective
psychoses.
Diagnosis in differentiated psychopathology was made by
repeated personal examinations of experienced psychia-
trists (BJ, GS). The probands were recruited from 1996 to
2005 at the Department of Psychiatry and Psychotherapy
at of the University of Würzburg. The Department serves
the city of Würzburg (130,000 inhabitants) and the sur-
rounding mostly rural area with a mean of 1150 admis-
sions per year and the full spectrum of psychiatric
disorders. With the endpoint in 2005, we assessed the
clinical data by chart analysis blind to genotyping (Table
1). Age at onset was defined as age at first contact with psy-
chiatric service, duration of disease was measured by the
period of time between first hospitalisation and age at
recruitment. The number and duration of in-patient treat-
ments was assessed for all hospitalisations for which med-
ical charts were available. The preponderance of males is
reflecting the recruitment procedure on wards for acutely
admitted males, and does not necessarily point towards
gender differences in affective psychoses. The 188 volun-
teer control subjects (105 males) with a mean age of 30.2
years were recruited from the blood donor centre at the
University of Würzburg. All subjects were unrelated and of
German Caucasian descent. The Ethics Committee of the
University of Würzburg had approved the study, and
informed consent was obtained from all subjects.
PCR for allelic discrimination was performed in a final
reaction volume of 20 μl containing 20 ng genomic DNA
and 10 μl of 2× TaqMan®Universal PCR Master Mix
(Applied Biosystems) and 1 μl of 20× TaqMan™ SNP gen-
otyping assay including fluorescent tags specific for theBMC Psychiatry 2006, 6:52 http://www.biomedcentral.com/1471-244X/6/52
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wild type allele and the variant allele. Marker amplifica-
tion was performed in microtiter plates on Biometra ther-
mocycles (Whatman). PCR amplification conditions were
according to the manufacturer's recommendation [10
min at 95°C followed by 15 sec at 92°C and 60 sec at
60°C for 40 cycles]. Allelic discrimination with endpoint
detection of fluorescence was performed at 60°C on an
ABI prism 7000 sequence detection system followed by
analysis with an appropriate software package (Applied
Biosystems). Allele calling was independently checked by
two operators blind to phenotype.
Fisher's exact test and Armitage's trend test were used to
compare allelic and genotypic distributions between cases
and controls. Haplotype frequencies and global associa-
tion were calculated with the program FAMHAP [12],
which does not specify a confidence interval for Odds
ratios. The exact test proposed by Weir [13] was applied
for Hardy-Weinberg equilibrium (HWE). For quantitative
traits, we performed the Kruskal-Wallis test and analysis
of variance (ANOVA) for single marker analysis and for
haplotypes by using haplotype trend regression (HTR)
[14]. Overall p-values were corrected for multiple testing
[12], the statistics on allele and genotype distribution
were uncorrected. Analyses were performed independ-
ently for the monopolar sample, the sample with manic-
depression, and the combined sample.
Results
Allele and genotype frequencies of rs4713916, rs1360780
and rs3800373 were not significantly different between
cases and controls (Table 2). We observed neither gender
differences nor differences in the clinical subgroups
according to differentiated psychopathology of monopo-
lar affective psychosis and manic-depression (data not
shown). For rs4713916, the genotype distribution in cases
deviated from HWE (P = 0.048) due to an excess of heter-
ozygous individuals. The standardized linkage disequilib-
rium (LD) among controls was D' = 0.751 for rs4713916
and rs1360780, D' = 0.750 for rs4713916 and rs3800373,
and D' = 0.971 for rs1360780 and rs3800373. A case-con-
trol study with 248 cases and 188 controls had a power of
80% to detect (at α = 0.05) an association with a suscep-
tibility allele, under the assumption that the susceptibility
allele has a population frequency of 0.3 and the effect of
this allele is recessive with a relative risk of 2.8.
In the studied population we found two haplotypes, G-C-
T and A-T-G, with a cumulated frequency of 86.2% in con-
trols (Table 3). Odds ratios were not increased between
cases and controls, except the rare haplotype G-C-G (OR
6.81) representing 2.1% of cases, and 0.3% of controls.
Analysis of FKBP5 genotypes and disease related variables
produced only one positive association: in monopolar
depression (n = 57) rs4713916AA was related to a short
duration of disease (P = 0.011; without Bonferroni's cor-
rection). Although rs1360780 has been previously
described as most significant marker [8], we observed no
association of rs1360780 with disease variables (Figure
1), such as age at first hospitalisation (ANOVA P = 0.98;
Kruskal-Wallis P = 0.94), number of in-patient treatments
(ANOVA P = 0.72; Kruskal-Wallis P = 0.53) or total period
in hospital (ANOVA P = 0.67; Kruskal-Wallis P = 0.49).
Likewise, the total period of in-patient treatment was not
statistically associated with specific genotypes of
rs4713916 (ANOVA P = 0.73; Kruskal-Wallis P = 0.82)
and rs3800373 (ANOVA P = 0.33; Kruskal-Wallis P =
0.32). We found no association of three-locus haplotypes
with clinical variables, neither in the sub-samples nor the
combined group (data not shown). Age at onset was nei-
ther associated with a distinct genotype nor with a specific
haplotype in any of the diagnostic subgroups. However,
Table 1: Demographic and disease related traits in the sample of probands with affective psychosis according to differentiated 
psychopathology
Monopolar depression (n = 57) Manic depressive illness (n = 191) Total sample (n = 248)
Male (n = 32) Female (n = 25) Male (n = 122) Female (n = 69) Male (n = 154) Female (n = 94) All cases (n = 248)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age at onset (years) 42.1 16.5 41.6 15.9 32.3 12.1 32.3 12.9 34.3 14.3 35.1 15.1 34.6 14.5
Age at first hospitalisation (years) 47.9 17.9 45.1 13.3 36.2 13.6 38.8 14.7 38.6 15.3 40.5 14.5 39.3 15.0
Age at assessment (years) 53.8 16.8 55.9 11.8 44.6 15.4 48.7 15.1 46.6 16.1 50.7 14.6 48.1 15.6
Period of time in hospital (sum in 
weeks)
33.2 24.8 47.8 53.2 38.5 56.6 46.9 58.9 37.4 51.6 47.1 57.2 41.1 53.9
Duration of disease at assessment 
(years)
12.3 14.2 14.6 8.4 12.9 11.2 16.5 13.4 12.8 11.9 15.0 13.0 14.0 12.4
Suicide attempts (number) 0.4 0.6 0.48 1.0 0.8 1.7 0.8 1.6 0.7 1.5 0.7 1.5 0.7 1.5
In-patient treatment (number) 3.4 2.8 5.8 4.9 4.8 6.9 5.1 4.8 4.5 6.3 5.3 4.8 4.8 5.8
SD: Standard deviationBMC Psychiatry 2006, 6:52 http://www.biomedcentral.com/1471-244X/6/52
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in the total sample the two-locus haplotype rs1360780T –
rs3800373G was associated with longer duration of dis-
ease at overall p-value of 0.045.
Discussion
At the FKBP5 locus allele and genotype frequencies of
rs4713916, rs1360780 and rs3800373 were not signifi-
cantly different between patients with affective psychoses
and controls. The putative risk haplotype G-C-G occurred
at a frequency of 2.1% among cases with odds ratio of 6.4.
Further findings were deviation of HWE among patients at
rs4713916, an association of rs4713916 (genotype analy-
sis) and rs1360780 – rs3800373 (two-locus haplotype
analysis) with duration of disease. However, we failed to
identify a clear-cut association of genetic markers with the
clinical course of affective psychosis in the total sample,
measured by age at onset, age of first hospitalisation, fre-
quency and period of in-patient treatment.
We confirm the notion of Binder and colleagues [8], that
none of the SNPs has a major effect on affective disorder,
neither with monopolar depression nor with manic
depression. Our sample consisted of German Caucasians
identical to the ethnicity of those in the study by Binder et
al [8]. The sample comprised 248 patients, 77% of them
with a diagnosis of manic depression in differentiated
psychopathology [10]. According to this conception, it is
possible to diagnose pretended depressive states as epi-
sodes of manic-depression if characteristic clinical fea-
tures are present. Based on these criteria, Pfuhlmann et al.
[11] emphasized manic-depression in this strict sense as a
nosological entity with an excessive familial morbidity
risk of 35.2% among first degree relatives compared to
cycloid psychosis (10.8%) and controls (5.7%) in a family
study on 431 relatives. In contrast, the sample of Binder et
al. [8] consisted of 87% cases with unipolar depression
among them an undetermined proportion with bipolar
background. It is estimated that at least 10% of unipolar
patients switch to a bipolar course in longitudinal studies
[15-17].
Regarding the power to detect an association, we had a
probability of 80% under the assumption that the suscep-
tibility allele has a population frequency of 0.3 and the
effect of this allele is recessive with a relative risk of 2.8 (at
α = 0.05). In addition, we observed a two-locus haplotype
rs1360780T – rs3800373G associated with a longer dura-
tion of disease regardless of the number of sustained epi-
sodes (overall P = 0.045) which is in contrast with the
observed risk haplotype (rs4713916G – rs1360780C –
rs3800373G). The main clinical findings by Binder and
colleagues [8] were related to the rare homozygous geno-
type rs1360780TT, located in intron 2 of FKBP5. The fre-
quency of 9.7% in the present sample was similar to the
previous data of 9.1%. Despite this congruence, we found
rs1360780TT not associated with an increased frequency
Table 3: Haplotype frequencies of markers at FKBP5 calculated by FAMHAP [11]
rs4713916 rs1360780 rs3800373 Controls (%) Cases (%) Odds ratio
G C T 64.3 60.7 0.86
A T G 21.9 24.8 1.18
A C T 4.8 5.2 1.10
G T G 4.4 3.6 0.80
A T T 2.4 2.1 0.88
G T T 1.7 1.4 0.82
G C G 0.3 2.1 6.81
A C G 0.3 0.1 0.51
Table 2: Allele and genotype distribution of polymorphisms spanning the FKBP5 locus
Controls Cases
Allele Genotype Allele Genotype
1 (%) 2 (%) 11 12 22 HWE 1 (%) 2 (%) P-value+ 11 12 22 HWE P-value*
rs4713916 A/G 110 (29.3) 266 (70.7) 18 74 96 0.50 160 (32.3) 336 (67.7) 0.38 19 122 107 0.048 0.12
rs1360780 C/T 262 (69.7) 114 (30.3) 94 74 20 0.35 338 (68.2) 158 (31.8) 0.66 114 110 24 0.73 0.86
rs3800373 T/G 275 (73.1) 101 (26.9) 102 71 15 0.60 344 (69.4) 152 (30.6) 0.23 115 114 19 0.20 0.87
HWE: P-value of Weir's test for Hardy-Weinberg Equilibrium
+: P-value of Fisher's exact test for comparison of allele frequencies between cases and controls
*: P-value of Armitage's trend test for comparison of genotype frequencies between cases and controlsBMC Psychiatry 2006, 6:52 http://www.biomedcentral.com/1471-244X/6/52
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of depressive episodes, although our sample had a mean
follow-up history of >10 years and a mean number of five
episodes requiring in-patient treatment. We assessed these
comprehensive clinical data in a retrospective chart analy-
sis, whereas the initial paper [8] mainly analyzed the ther-
apeutic outcome of a single episode in a naturalistic
setting over five weeks. Unlike Binder and colleagues [8]
we found weak evidence for involvement of rs4713916,
located at the presumed promoter region in the vicinity of
a putative glucocorticoid response element [4]. Genotype
distribution for rs4713916 in patients deviated from
HWE and a longer continuance of disease was associated
with rs4713916AA in monopolar depression (P = 0.011).
Thus, our results may be the effect of chance findings due
to sample stratification, although haplotype and haplo-
type-related analyses were based on permutation-based
tests.
Given the differences of LD between the promoter region
and distal areas, different genetic variants may be relevant
at FKBP5 in depression. Variants at the promoter region
may influence the transcription of FKBP5, whereas other
functional variants in downstream regions may act as
independent risk factors in other cases [18]. Reflecting the
complex phenomenology of depression, FKBP5 may play
a decisive role only in some cases of depression, and other
genes involved in the glucocorticoid system are responsi-
ble for the disturbances of the HPA-axis during depressive
episodes [19,20]. FKBP5 could be linked to several basic
mechanisms of stress related phenomena, as polymor-
phisms in FKBP5 were associated with peritraumatic dis-
sociation in medically injured children [21].
Conclusion
In summary, our data do not support a significant genetic
contribution of FKBP5 to affective psychosis in the ana-
lysed markers, and the findings are inconclusive regarding
precisely associated polymorphisms and haplotypes and
their association with disease-related traits.
Genotype-specific mean values of clinical variables in depressive patients for three SNPs in FKBP5 (n = 248) Figure 1
Genotype-specific mean values of clinical variables in depressive patients for three SNPs in FKBP5 (n = 248). 
Using ANOVA and Kruskal-Wallis tests none of the markers reached statistical significance for association with disease-related 
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